Changes in the qualitative and quantitative secretion of luteinizing hormone (LH) following orchidectomy in man.
Affiliation
Department of Endocrinology, Christie Hospital, Manchester, UK.Issue Date
1988-08
Metadata
Show full item recordAbstract
The effect of orchidectomy and thus withdrawal of testicular hormones on the biological and immunological properties of plasma LH was studied. Plasma samples were obtained from five men (mean age 71, range 65-81 years) with advanced carcinoma of the prostate, before orchidectomy and 1, 4, 8 and 16 weeks after surgery. LH bioactivity was estimated by a mouse Leydig cell bioassay and immunoreactivity by radioimmunoassay, using the same human pituitary LH standard 68/40. FSH and testosterone were measured by radioimmunoassay. Similar baseline data were obtained from a group (n = 17) of normal adult men (26, 19-36 years). Baseline bioactive (40 IU/l, median) and immunoreactive (10.8 IU/l) LH levels in the patients were higher (P less than 0.01) than in the controls (15.1 and 5.7 IU/l respectively), but bioactive to immunoreactive (B:I) LH ratios (3.4 +/- 0.2 versus 2.8 +/- 0.7) and testosterone levels (15.3 vs 18.7 nmol/l) were no different, consistent with compensated Leydig cell failure in the elderly men. After orchidectomy there was a greater increase in immunoreactive (46.6 IU/l at 16 weeks) than bioactive (80.3 IU/l) LH levels i.e. a fourfold vs twofold increase from baseline values. Consequently the B:I LH ratio decreased significantly (1.8 +/- 0.4 at 16 weeks) from the baseline ratio (P less than 0.0001) and that of the controls (P less than 0.01). These data indicate that acute withdrawal of testicular sex steroids results not only in quantitative change in LH secretion but also in qualitative change that decreases the biopotency of the LH molecules.Citation
Changes in the qualitative and quantitative secretion of luteinizing hormone (LH) following orchidectomy in man. 1988, 29 (2):189-94 Clin EndocrinolJournal
Clinical EndocrinologyDOI
10.1111/j.1365-2265.1988.tb00260.xPubMed ID
3150321Type
ArticleLanguage
enISSN
0300-0664ae974a485f413a2113503eed53cd6c53
10.1111/j.1365-2265.1988.tb00260.x
Scopus Count
Collections
Related articles
- The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay.
- Authors: Jaakkola T, Ding YQ, Kellokumpu-Lehtinen P, Valavaara R, Martikainen H, Tapanainen J, Rönnberg L, Huhtaniemi I
- Issue date: 1990 Jun
- Effects of oestrogen treatment on serum gonadotrophin bioactivity, immunoreactivity and isohormone distribution, and on immunoreactive inhibin levels, in prostatic cancer patients.
- Authors: Matikainen T, Haavisto AM, Permi J, de Kretser D, Huhtaniemi I
- Issue date: 1994 Jun
- The pulsatile secretion of bioactive luteinising hormone in normal adult men.
- Authors: Talbot JA, Rodger RS, Shalet SM, Littley MD, Robertson WR
- Issue date: 1990 May
- Age related changes in the pituitary-testicular axis in normal men; lower serum testosterone results from decreased bioactive LH drive.
- Authors: Mitchell R, Hollis S, Rothwell C, Robertson WR
- Issue date: 1995 May
- Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy.
- Authors: Huhtaniemi IT, Dahl KD, Rannikko S, Hsueh AJ
- Issue date: 1988 Feb